Category Archives: Hypogonadism

By John Vandermosten NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Up and Coming Milestones Tlando PDUFA date August 28, 2020 Primary endpoint results for LiFT (LPCN 1144) 4Q:20 Patent Infringement trial February 2021 Complete Phase II LiFT (LPCN 1144) 2Q:21 Second Quarter 2020 Operational and Financial Results On August 6, 2020 Lipocine (NASDAQ:LPCN) filed its second quarter 2020 10-Q and posted its earnings release for the three month period ending June 30, 2020. The company reported zero revenues and a net loss per share of ($0.13) compared to prior year revenues of zero and loss of ($0.14) per share. Continue reading →

BUFFALO, N.Y. Continue reading →

Aytu BioScience's Sublicensee SUDA Pharmaceuticals Secures TGA Approval, Enabling Near-Term Commercialization of ZolpiMist ENGLEWOOD, CO / ACCESSWIRE / July 30, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the approval of ZolpiMist (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia. This approval, which was secured by the Company's ZolpiMist sublicensee SUDA Pharmaceuticals Ltd ("SUDA"), enables near-term commercialization of ZolpiMist in Australia. Continue reading →

Andropause or male menopause has to do with the declining hormonal levels in older men. Read on to know the symptoms, causes and treatment of this condition. We often talk about how women suffer from menopause and how it affects their health. Continue reading →

Male Hypogonadism Market Industry Forecast To 2026 Garner Insights has titled a new research report named as Male Hypogonadism Market 2020 to its consistently extending database. The report clarifies this through a series of channels which include data ranging from rudimentary data to an undeniable estimate Continue reading →

The global Male Hypogonadism market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Male Hypogonadism market player in a comprehensive way. Continue reading →

Steroid is an organic compound that has 4 cyclo-alkane rings connected to each other. Steroid consist of 20 carbon atoms. Steroid market is growing owing to increasing demand from the weightlifters and sport industry. Continue reading →

Male Hypogonadism Market report provides a thorough synopsis on the study for market and the way its dynamical first rudiment business. This report analyzes the potential of the Market in the present and also the future prospects from numerous angles well Continue reading →

Testosterone therapy ads promise to help aging men recapture their vitality, decrease body fat and enhance libido. But hormone treatments while medically necessary for some men arent meant to be a fountain of youth, and experts warn more research is needed to determine if such therapy could boost heart disease risks. Testosterone levels naturally decline in most men as they age Continue reading →

New data from phase 3 clinical trials provide further evidence supporting the safety and effectiveness of the first-to-market oral testosterone undecanoate treatment for hypogonadism (Jatenzo), reported Stanton Honig, MD. Honig presented results for secondary end points from 2 randomized studies comparing the lipoprotein-coated testosterone undecanoate formulation with topical testosterone treatments showing that both the oral and gel products were associated with statistically significant improvements in psychosocial well-being and bone and body composition parameters Continue reading →